Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NKARTA INC (NKTX) Stock Price & Overview
NASDAQ:NKTX • US65487U1088
Current stock price
2.93 USD
+0.16 (+5.78%)
At close:
2.95 USD
+0.02 (+0.68%)
After Hours:
The current stock price of NKTX is 2.93 USD. Today NKTX is up by 5.78%. In the past month the price increased by 26.29%. In the past year, price increased by 40.19%.
NKTX Key Statistics
52-Week Range1.63 - 3.65
Current NKTX stock price positioned within its 52-week range.
1-Month Range2.13 - 3.65
Current NKTX stock price positioned within its 1-month range.
- Market Cap
- 208.88M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.40
- Dividend Yield
- N/A
NKTX Stock Performance
Today
+5.78%
1 Week
+0.34%
1 Month
+26.29%
3 Months
+31.98%
Longer-term
6 Months +38.86%
1 Year +40.19%
2 Years -56.85%
3 Years -36.58%
5 Years -87.97%
10 Years N/A
NKTX Stock Chart
NKTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NKTX. When comparing the yearly performance of all stocks, NKTX is one of the better performing stocks in the market, outperforming 86.01% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. While NKTX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NKTX Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported
EPS Surprise -14.07%
Revenue Surprise %
NKTX Forecast & Estimates
12 analysts have analysed NKTX and the average price target is 12.24 USD. This implies a price increase of 317.75% is expected in the next year compared to the current price of 2.93.
Analysts
Analysts85
Price Target12.24 (317.75%)
EPS Next Y-9.14%
Revenue Next YearN/A
NKTX Index Membership
NKTX is currently included in the following stock indexes tracked on ChartMill.
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 15.66% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-104.08M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.75% | ||
| ROE | -33.33% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-5.71%
Sales Q2Q%N/A
EPS 1Y (TTM)15.66%
Revenue 1Y (TTM)N/A
NKTX Ownership
Ownership
Inst Owners77.93%
Shares71.29M
Float67.49M
Ins Owners0.47%
Short Float %8.01%
Short Ratio6.68
NKTX Industry Overview
NKTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
NKTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Company Info
IPO: 2020-07-10
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 108
Phone: 19254071049
NKARTA INC / NKTX FAQ
What does NKARTA INC do?
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
What is the stock price of NKARTA INC today?
The current stock price of NKTX is 2.93 USD. The price increased by 5.78% in the last trading session.
What is the dividend status of NKARTA INC?
NKTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NKTX stock?
NKTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for NKTX stock?
NKARTA INC (NKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
Can you provide the market cap for NKARTA INC?
NKARTA INC (NKTX) has a market capitalization of 208.88M USD. This makes NKTX a Micro Cap stock.
When does NKARTA INC (NKTX) report earnings?
NKARTA INC (NKTX) will report earnings on 2026-05-07.